Infectious Disorders
Prion diseases
Dec. 12, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Japanese encephalitis …
- Updated 08.27.2024
- Released 08.17.2000
- Expires For CME 08.27.2027
Japanese encephalitis
Introduction
Overview
The Japanese encephalitis virus is a flavivirus and a mosquito-borne human pathogen. It is the world’s most important cause of viral encephalitis and is present in many countries in Asia, causing nearly 68,000 clinical cases every year. The case fatality rate can be as high as 30%. Permanent neurologic or psychiatric sequelae can occur in 30% to 50% of patients. Children are more frequently and severely affected. A paradigm shift in epidemiology has been observed as Japanese encephalitis is becoming increasingly common among adults due to expanding Japanese encephalitis transmission areas, improved control in children leading to more adult cases, and increased tourism to Japanese encephalitis risk areas. Several reports describe increasing numbers of cases of Japanese encephalitis among Western travelers returning from Asia. An observation noted that TLR3 gene polymorphism might confer host genetic susceptibility to Japanese encephalitis in Indian populations. The clinical features of Japanese encephalitis virus infection range from a nonspecific flu-like illness to a severe and often fatal meningoencephalomyelitis. MRI characteristically shows high-signal lesions in the thalamus and substantia nigra. A report from China recorded 47 patients with Japanese encephalitis who presented with Guillain-Barré syndrome. In the majority, Guillain-Barré syndrome was of the acute motor axonal neuropathy variety. A study of 1626 patients with Japanese encephalitis (2016–2020) found 230 (14%) with peripheral nerve injury, leading to higher mortality (16%) and longer hospital stays (103). Japanese encephalitis infection can also trigger anti-N-methyl-d-aspartate receptor (NMDAR) immunoglobulin G (IgG) synthesis. No specific antiviral therapy is available for Japanese encephalitis. In a small trial, combination immunotherapy that included immunoglobulin, ribavirin, and interferon alpha-2b was effective. Treatment is otherwise mainly supportive and symptomatic. Intravenous immunoglobulin has been shown to augment the development of neutralizing antibodies in patients with Japanese encephalitis, and it may be used as a therapeutic agent in the future. Vaccination of the population at risk is the method of choice for prevention. The inactivated mouse brain-derived vaccines have now been replaced by cell culture–based vaccines. In this article, the author has reviewed in detail the various aspects of Japanese encephalitis.
Key points
|
• Japanese encephalitis virus is a neurotropic flavivirus that is the causative agent of the major mosquito-borne encephalitis in the world. | |
|
• Among 68,000 annual cases of Japanese encephalitis, approximately 30% die, and up to 50% of survivors may have sequelae. | |
|
• Japanese encephalitis, in the endemic areas, is regarded as a disease of children. | |
|
• Japanese encephalitis dominantly affects the thalamus, corpus striatum, brainstem, and spinal cord. | |
|
• Japanese encephalitis manifests with altered sensorium, seizures, and focal neurologic deficit. | |
|
• Japanese encephalitis should be considered as a diagnostic possibility in travelers developing encephalitis after travel to endemic areas. | |
|
• In the absence of effective antiviral therapy, Japanese encephalitis treatment is symptomatic and supportive. | |
|
• The main measure for Japanese encephalitis prevention is the use of a live attenuated vaccine for humans. |
Historical note and terminology
Since the end of the 19th century, Japanese encephalitis has been recognized as a scourge of the orient. Epidemics of encephalitis have been described in Japanese literature since 1870, with thousands of cases recorded in some years. In 1933 a filterable agent was transferred from the brain of a fatal case and used to cause encephalitis in monkeys; the virus was then isolated in 1935. The term “Japanese B encephalitis” was used originally to distinguish these summer epidemics from Von Economo's “encephalitis lethargica” (labeled type A) (43). The term “B” has since been dropped. The virus was subsequently classed as a member of the genus flavivirus (family Flaviviridae), named after the prototype Yellow fever virus (in Latin, flavus means yellow). Although of no taxonomic significance, the ecological term “arbovirus” is often used to describe the fact that Japanese encephalitis virus is arthropod (insect) borne. A vaccine developed by Albert Sabin (later of poliomyelitis fame) and others during World War II has been available for 30 years. Despite the existence of this vaccine, Japanese encephalitis has grown as a problem in the last 50 years because of its geographical spread and increased incidence. The disease threatens both residents and travelers in endemic areas and is one of the most important emerging arboviruses (87).
Clinical manifestations
Presentation and course
The clinical features of Japanese encephalitis virus infection range from a nonspecific flu-like illness to a severe and often fatal meningoencephalomyelitis. Children with Japanese encephalitis typically present after a few days of febrile illness, which may include coryza, diarrhea, and rigors. This is followed by headache, vomiting, and a reduced level of consciousness often heralded by a convulsion.
In a proportion of patients, recovery is rapid and spontaneous (“abortive encephalitis”). Others present with aseptic meningitis and have no encephalopathic features. The classical description of Japanese encephalitis includes a dull, flat “mask-like” face with wide unblinking eyes, tremor, generalized hypertonia, and cogwheel rigidity. These parkinsonian features were reported in 20% to 40% of Asian children and 70% to 80% of American service personnel (59; 52; 23). Rigidity spasms, particularly on stimulation, occur in about 15% of patients and are associated with a poor prognosis (52). Other extrapyramidal features include head nodding and pill rolling movements, facial grimacing, lip-smacking, opisthotonus, and choreoathetosis (52; 88).
Convulsions occur frequently in Japanese encephalitis and are reported in up to 85% of children and 10% of adults (24; 52). Multiple or prolonged seizures and status epilepticus (especially subtle motor status epilepticus) are also associated with a poor prognosis (94; 89). In a comparative study, neck rigidity, convulsions, abnormal behavior, seizures, and elevated aspartate transaminase are more frequent in pediatric patients than adults. Cerebrospinal fluid abnormalities were more frequent in adult patients (08). In a large adult study (1282 patients) altered sensorium, convulsions, and headache were the main presenting symptoms. Movement disorders (eg, hyperkinetic movements and choreoathetoid and bizarre, ill-defined movements) were frequently encountered. The features of brainstem involvement consisted of opsoclonus, gaze palsies, and pupillary changes with waxing and waning character. Cerebellar signs were distinctly absent. Other manifestations included dystonia, decerebrate rigidity, and paralysis. Nonneurologic features of prognostic importance included abnormal breathing patterns, pulmonary edema, and upper gastrointestinal hemorrhage (80).
A subgroup of patients with Japanese encephalitis presented with a polio-like acute flaccid paralysis presentation (92). In these patients, a short febrile illness was followed by a rapid onset of flaccid paralysis in one or more limbs despite a normal level of consciousness (22). Weakness occurred more frequently in the legs than the arms and was usually asymmetrical. Thirty percent of such patients subsequently developed encephalitis, with reduced level of consciousness and upper motor neuron signs, but in the majority, acute flaccid paralysis was the only feature. At follow-up there was persistent weakness and marked wasting in the affected limbs. Nerve conduction studies demonstrated markedly reduced motor amplitudes, and electromyography showed chronic partial denervation, suggesting anterior horn cell damage (92). Flaccid paralysis also occurs in patients with “classical” Japanese encephalitis. It is reported in 5% to 20% of comatose patients (24) and is associated with abnormal signal intensity on T2 weighted MRI images of the spinal cord (55).
Wang and colleagues reported data on 47 patients with Japanese encephalitis who presented with Guillain–Barré syndrome (102). CSF evaluation, in 38 patients, revealed albumin-cytologic dissociation. In the majority (47%) of patients, Guillain-Barré syndrome was of acute motor axonal neuropathy variety. In 18 cases Guillain-Barré syndrome was of acute motor-sensory axonal neuropathy type. Acute inflammatory demyelinating polyneuropathy and acute sensory neuropathy verities were noted in four and three patients, respectively. Twenty-eight patients were treated with intravenous immune globulin. Half of these responded well to intravenous immune globulin treatment (102).
A report from Indonesia revealed that Japanese encephalitis virus infection was even prevalent in patients with non-encephalitic acute febrile illness (64). Serum specimens of 144 patients with acute febrile illness was tested for anti-Japanese encephalitis virus IgM antibody. Twenty-six (18%) patients either had confirmed anti-Japanese encephalitis virus IgM antibody positivity or demonstrated equivocal results. Five (3.5%) and eight (5.6%) patients, respectively, were able to fulfill the criteria for confirmed or probable Japanese encephalitis infection (64).
Prognosis and complications
The case-fatality rate among those with symptomatic Japanese encephalitis can be as high as 30%. Permanent neurologic or psychiatric sequelae can occur in 30% to 50% of patients (11; 108). Fixed flexion deformities of the arms, and hyperextension of the legs with “equine feet” are common. Twenty percent of patients have severe cognitive and language impairment (most with motor impairment too) and 20% have further convulsions (41). A higher rate of sequelae is reported for children than adults (83). More detailed studies have suggested that approximately half of those who were classed in the “good recovery” group have more subtle sequelae such as learning difficulties, behavioral problems, and subtle neurologic signs (53). The long-term prognosis of Japanese encephalitis was assessed in Malaysia. In this study 118 patients were recruited. Ten patients (8%) died during the acute phase of illness. At hospital discharge, 44 (41%) of the 108 patients who survived had apparent full recovery; 33 (31%) patients had severe neurologic sequelae (74). On long-term follow-up, more than one half of the patients continued to experience neuropsychological sequelae and behavioral disorders. A combination of poor peripheral perfusion, with prolonged capillary refill time (greater than 2 sec), Glasgow coma score (8 or less), and two or more witnessed seizures predicted a poor long-term outcome with 65% sensitivity and 92% specificity (74).
Chen and colleagues evaluated long-term neurologic complications and mortality in 352 adult patients with Japanese encephalitis (16). Stroke was the most common neurologic complication, followed by epilepsy and convulsions, encephalopathy and delirium, and parkinsonism. A study was conducted on 328 children with Japanese encephalitis to determine the risk factors of postencephalitic epilepsy and construct a risk prediction model. In the study, 65.9% of the children had seizures in the acute phase, and 14.7% developed postencephalitic epilepsy. Seizure number greater than 5, status epilepticus, and coma were identified as independent risk factors for postencephalitic epilepsy (15).
A retrospective, multicenter study of 1626 patients with Japanese encephalitis from the Chinese Center for Disease Control and Prevention (2016–2020) identified 230 (14%) with peripheral nerve injury (103). These patients with peripheral nerve injury, primarily in northwest China, exhibited acute flaccid paralysis and severe respiratory muscle paralysis necessitating longer hospital and intensive care unit stays. The mortality rate was higher in these patients (16%) compared to patients without peripheral nerve injury (5%).
Japanese encephalitis is a risk for travelers who visit Japanese encephalitis-endemic countries. Hills and colleagues reviewed all published Japanese encephalitis cases in travelers from nonendemic areas from 1973 through 2008 and assessed factors related to risk of infection. The authors collected 55 cases that occurred in citizens of 17 countries. Ten (18%) persons died, and 24 (44%) had mild to severe sequelae (36).
Clinical vignette
A 13-year-old Vietnamese boy presented with progressive leg weakness. On the first two days of illness, he had fever, headache, vomiting, and neck stiffness. By day three he had progressive weakness of the left leg, which was painful. This was followed by weakness and pain in the right leg and lumbar spine. By day five he was unable to walk or sit unsupported and was brought to a hospital. He had no past symptoms or family history of note, and had been fully vaccinated against diphtheria, tetanus, and polio. On examination he was fully conscious, with neck stiffness. His temperature was 40.3 C; pulse was 130 beats per minute, and respiratory rate was 38 breaths per minute. The cardiovascular, respiratory, and abdominal examination was otherwise unremarkable. The cranial nerves and upper limbs were completely normal. He had marked flaccid weakness of both legs with the Medical Research Council grade 0/5 in all groups except the ankles and great toes, which were 1/5. Deep tendon reflexes in the legs were absent, as were the abdominal and cremasteric reflexes. Light touch, pinprick, and joint position sensation were normal in the legs, but the skin and muscles were tender. Perineal sensation was normal.
Thick and thin blood films were negative for malaria parasites. Hematocrit was 37%; there was a peripheral leukocytosis with 16,000 white cells/mm3 (69% neutrophils). Platelets, urea, and electrolytes were normal. A lumbar puncture had an opening pressure of 100mm CSF, two white cells/mm3, and 84 red cells/mm3; protein was elevated at 74 mg/dL, and the glucose was 51mg/dL (plasma glucose 51mg/dL). Gram stain and bacterial culture were negative. A chest x-ray was normal, Mantoux test was negative, and stool culture was negative for enteroviruses, including poliovirus. An IgM capture dot enzyme immunoassay for Japanese encephalitis virus was positive in both CSF and serum (93); this was confirmed by an IgM ELISA, which showed 186 units in the CSF and 153 units in the serum (normal levels are less than 40 units).
His fever continued, and on day seven of the illness he became confused (Glasgow coma score eyes=3, motor=5, verbal=4). There were no clinical signs of raised intracranial pressure and no new focal signs. A guide airway was inserted, and he was fed via a nasogastric tube. By day 10 he was fully conscious, and motor function was slowly improving. When he was discharged from the hospital 2 months later, he could walk with a waddling gait. At a 1-year follow-up, his gait was still abnormal and there was muscle wasting, more marked in the right leg than the left (91).
Biological basis
Etiology and pathogenesis
Japanese encephalitis is caused by the flavivirus Japanese encephalitis virus, which has a small (50 nm) lipoprotein envelope surrounding a nucleocapsid comprising of core protein and 11 KB single stranded RNA (3800 kD). There are at least five genotypes of Japanese encephalitis virus in Asia (18; 17; 99) and several closely related neurotropic flaviviruses occur across the globe (88; 86). In Australia, Murray Valley encephalitis virus causes sporadic encephalitis cases and occasional epidemics, and St. Louis encephalitis virus causes a similar disease in America. West Nile virus was previously confined to Africa, Europe, and the Middle East, but arrived in North America in 1999 (09) and has since spread across the continent to cause large outbreaks (75).
The nucleotide sequence of Japanese encephalitis virus includes 5’ and 3’ untranslated regions, genes for seven non-structural proteins and three structural proteins. One of these, the envelope protein, is the major component of the surface projections of the virion and is thought to bind to cells and mediate membrane fusion and cell entry (72). A highly sulphated heparan sulphate molecule has been identified as the putative receptor of flavivirus cell entry (19). In animal models of Japanese encephalitis, the envelope protein plays a role in determination of virulence phenotypes, but whether this is important in determining the clinical presentation of human infections is unknown.
Almost all children living in endemic areas become infected with the Japanese encephalitis virus, but only about 1 in 25 to 1 in 1000 develops clinical features (100). Factors determining which of those infected will develop disease are unknown but could include viral factors such as route of entry, titer, and virulence or host factors such as age, genetic make-up, general health, and preexisting immunity. An observation noted that TLR3 gene polymorphism might confer host genetic susceptibility to Japanese encephalitis in Indian population (07).
In endemic areas, humans become infected with Japanese encephalitis virus after mosquito bites. The Japanese encephalitis virus multiplies locally and in regional nodes. After a phase of transient viremia, invasion of the central nervous system occurs via hematogenous spread. In the neurons, the virus replicates and matures in the neuronal secretory system, mainly the rough endoplasmic reticulum and Golgi apparatus, eventually destroying these structures (98). In an experimental study, authors demonstrated that the permeability of the blood-brain barrier changed in response to viral infection, leading to the entry of Japanese encephalitis virions or putatively infected leukocytes from the periphery to the cerebrum as the initial site of infection in the central nervous system (62).
At autopsy, CNS findings in Japanese encephalitis reflect the inflammatory response to widespread neuronal infection with the virus (70; 46). The thalamus, basal ganglia, midbrain, cerebellum, and anterior horns of the spinal cord are heavily affected, providing anatomical correlates for the tremor, dystonias, and flaccid paralysis that characterize the disease. Pathologic changes in the brains of patients with acute Japanese encephalitis are characterized by glial nodules and circumscribed necrolytic foci. Focal regions of white matter involvement are also present (31).
Invasion of neurons by the Japanese encephalitis virus is followed by perivascular cuffing, infiltration of inflammatory cells into the parenchyma, and phagocytosis of infected cells. There may be no histological signs of inflammation in patients who die rapidly, but immunohistochemical studies reveal viral antigen in morphologically normal neurons (46). This may explain the normal CSF findings in a proportion of patients with Japanese encephalitis. One study used routine histological staining, immunohistology, and electron microscopy to examine brain material from four fatal human cases and made comparisons with material from a mouse model (28). In human material there was edema, perivascular inflammation, hemorrhage, microglial nodules, and acellular necrotic foci, as has been described previously. In addition, new evidence was suggestive of viral replication in the vascular endothelium, with endothelial cell damage. Viral antigen was also found in neurons.
Both humoral and cellular immunity appear to be important in Japanese encephalitis. The humoral immune response has been well characterized. In primary infection (ie, when Japanese encephalitis virus is the first flavivirus with which an individual has been infected) a rapid and potent IgM response occurs in serum and CSF within days of infection. Most patients have elevated titers by day 7 and attempts to isolate virus are usually negative in such patients (10). However, the failure to mount an IgM response is associated with positive virus isolation and a fatal outcome (56; 58). Asymptomatic infection with Japanese encephalitis virus is also associated with elevated IgM in the serum, but not CSF (10). In patients with secondary infection (ie, those who have previously been infected with a different flavivirus such as dengue infection or yellow fever vaccination), there is an anamnestic response to flavivirus group common antigens (10). This secondary pattern of antibody activation is characterized by an early rise in IgG with a subsequent slow rise in IgM.
The cellular immune response appears to contribute to the prevention of disease in animal models of Japanese encephalitis by restricting virus replication before the CNS is invaded. In humans, specific T cell responses (including CD8+ T lymphocyte proliferation and CD4+ T lymphocyte responses that recognize the envelope protein in a HLA restricted manner) have been demonstrated in convalescent patients with Japanese encephalitis and vaccine recipients (01). Proliferate responses to the virus’ PrM, E, NS1, NS3 and NS5 have been reported for T cells from humans that had previously had subclinical infections with Japanese encephalitis virus (50). Memory T cells responses to NS-3 were especially common, with IFN-g production in both CD4+ and CD8+ T cells consistent with a Th1-type response (49). Interestingly, patients 6 months after hospital discharge had similar proliferative responses to healthy Japanese encephalitis virus-exposed individuals but produced less IFN-g (measured by ELISA) (48).
Observations suggest that the increased microglial activation following Japanese encephalitis virus infection influences the outcome. It is likely that the increased microglial activation triggers bystander neuronal damage (29). Experimental studies suggest that neuronal apoptotic death and activation of microglial cells and astrocytes play a crucial role in the pathogenesis of Japanese encephalitis. The Japanese encephalitis virus induces neuronal apoptotic death and release of cytokines that initiate microglial activation and release of proinflammatory and apoptotic mediators with subsequent apoptotic death of both infected and uninfected neurons. Activation of astrocytes and microglial and endothelial cells likely contributes to inflammatory cell recruitment and blood-brain barrier breakdown (73). Proinflammatory cytokine and chemokine levels in the CSF are associated with a bad outcome in patients with Japanese encephalitis (104).
Epidemiology
Culex mosquitoes transmit Japanese encephalitis virus in an enzootic cycle that involves pigs, chickens, and other birds. The most important vector for human infections is Culex tritaeniorhynchus, which breeds in pools of stagnant water such as rice paddy fields (43). Humans become infected with Japanese encephalitis virus coincidentally when living or traveling in close proximity to the virus’ enzootic cycle. In rural Asia, the majority of the population is infected during childhood or early adulthood (38). Approximately 10% of the susceptible population is infected each year but most infections of humans are asymptomatic or result in a non-specific flu-like illness. Humans are considered the dead-end host, as the brief periods of viremia and low viral titers do not facilitate further transmission of the virus.
Japanese encephalitis is the most important cause of viral encephalitis in many countries of Asia, with nearly 68,000 clinical cases every year. The annual incidence of clinical disease varies (both across and within countries), ranging from less than 10 to more than 100 per 100,000 population. The case-fatality rate can be as high as 30%. Permanent neurologic or psychiatric sequelae can occur in 30% to 50% of patients. Twenty-four countries in the World Health Organization South-East Asia and Western Pacific regions have endemic Japanese encephalitis transmission, exposing more than 3 billion people to risks of infection. Japanese encephalitis primarily affects children. Most adults in endemic countries have natural immunity after childhood infection, but individuals of any age may be affected (11; 108). In northern areas (northern Vietnam, northern Thailand, Korea, Japan, Taiwan, China, Nepal, and northern India) huge epidemics occur during the summer months, whereas in southern areas (southern Vietnam, southern Thailand, Indonesia, Malaysia, Philippines, Sri Lanka, and southern India) Japanese encephalitis tends to be endemic: cases occur sporadically throughout the year with a peak after the start of the rainy season (100). These differences probably relate to climate and vector abundance, but viral genotypes and host susceptibilities may also be important. Japanese encephalitis surveillance has been conducted since 1965 as a part of the National Epidemiological Surveillance of Vaccine Preventable Diseases in Japan. Over 1000 Japanese encephalitis cases were reported annually in the late 1960s. The number of Japanese encephalitis cases has since markedly decreased, with less than 10 cases reported annually from 1992 to 2004. A total of 361 Japanese encephalitis cases were reported between 1982 and 2004. Prognosis was available for 320 cases; 58 (18%) died, 160 (50%) recovered with neuropsychiatric sequelae, and 102 (32%) completely recovered. Seventy-eight percent of these cases were 40 years old or over with a peak age group of 60 to 69 years of age. Japanese encephalitis predominantly occurred in unvaccinated populations (03). One report described three cases of Japanese encephalitis among United States travelers returning from Asia (12). All were Asian immigrants or family members who traveled to Asia and had not been vaccinated for Japanese encephalitis. These three patients experienced fever with mental status changes, but Japanese encephalitis was recognized early in the clinical course of only one patient. All recovered, but two patients had residual neurologic deficits. Data from an endemic region noted that 26.9%, 9·9%, and 14.8% of acute encephalitic syndrome cases were positive CSF serology for Japanese encephalitis in the years 2011, 2012, and 2013, respectively. Of the total Japanese encephalitis confirmed cases, 30% were adults. Males were more commonly affected than females. Japanese encephalitis outbreak was seen in the monsoon and post-monsoon season (44). In Uttar Pradesh, a heavily populated province of North India, there were 47,509 reported cases of acute encephalitis syndrome between 2005 to 2018 (84). Among patients of acute encephalitis syndrome, approximately 10% had confirmed Japanese encephalitis.
Japanese encephalitis is, generally, considered a disease of young children (109). A Chinese report noted that even older adults are equally liable to be affected with Japanese encephalitis. In 2018, 1800 Japanese encephalitis cases were reported in China; 64% of these cases were adults aged 40 years or older.
The geographical area affected by Japanese encephalitis virus has expanded in the last 50 years. Epidemics have occurred in China since 1935, in South Korea since the late 1940s, and in Vietnam and Thailand since the mid-1960s (100). The disease was recognized in southern India in 1955, but since the 1970s large outbreaks have occurred further north. Epidemics in Nepal have confirmed the continuing spread of Japanese encephalitis in a northwestern direction (02). The disease has also spread across Southeast Asia and the Pacific Rim, reaching mainland Australia for the first time in 1998 (33).
The reasons for the spread of Japanese encephalitis are not completely understood, but may include changing agricultural practices, such as increasing irrigation (which allows mosquito breeding) and animal husbandry (which provides host animals). In developed countries such as Japan, Taiwan, and South Korea, the number of cases of Japanese encephalitis has fallen, probably due to a combination of factors including mass vaccination of children and socioeconomic changes (88). However, in Korea the widespread use of vaccine in children has been associated with a higher incidence of Japanese encephalitis in those over 15 years of age (100).
An outbreak of Japanese encephalitis virus has occurred in Australia, with 40 confirmed or probable human cases reported, including five deaths. A cross-sectional serosurvey in five high-risk New South Wales towns during the 2022 Japanese encephalitis outbreak found that 8.7% of 917 participants were seropositive for Japanese encephalitis virus–specific antibodies (05). The highest seropositivity was among people aged 65 and older (13.7%); seropositivity was higher in males (10.6%) than in females (7.5%). This is the first Japanese encephalitis outbreak in Australia since 1998, and it has been linked to genotype 4 Japanese encephalitis closely related to strains in Indonesia. The introduction of Japanese encephalitis into Australia is thought to be facilitated by infected migratory birds, mosquitoes, or both, with transmission to pigs leading to virus amplification. Contributing factors to the outbreak include La Niña weather conditions, intensive pig farming, and a large feral pig population. Mosquitoes, particularly Culex annulirostris, are the primary vector, presenting challenges for identifying at-risk groups and controlling the spread of the virus (101; 110).
A paradigm shift in epidemiology has been observed as Japanese encephalitis is becoming increasingly more common among adults due to expanding Japanese encephalitis transmission areas, improved Japanese encephalitis control in children leading to more adult cases, and increased tourism to Japanese encephalitis risk areas. Clinical presentation and severity of illness are similar for both adults and children, with the only clear difference being a lower frequency of seizures in adults. Childhood vaccination programs in endemic areas should be strengthened and maintained to reduce the burden of disease in both children and adults (37).
Prevention
Measures to control Japanese encephalitis include those that interfere with the virus’ enzootic cycle and those that prevent human infection, including vaccines. Attempts to control breeding of Culex mosquitoes and vaccination of pigs have mostly proved ineffectual. Efforts to reduce the number of Culex bites, such as minimizing exposed skin and using insect repellents containing DEET (N,N-diethyl-3methlybenzamide) are advisable for short-term visitors, but are often not practical for permanent residents. All travelers to Japanese encephalitis-endemic areas should take precautions to avoid mosquito bites to reduce the risk for Japanese encephalitis. Personal preventive measures, like use of repellents, long-sleeved clothes, and coils and vaporizers, are recommended (108).
The most widely used vaccine for Japanese encephalitis virus is a mouse brain-derived vaccine developed in Japan and based on the Nakayama or Beijing-1 strain. Its efficacy was shown in large double-blind randomized tetanus-toxoid controlled trials in Taiwan and Thailand involving more than 300,000 children (38; 82). Although it is associated with a moderate frequency of mild side effects, serious neurologic adverse events are very rare. Encephalitis, encephalopathy, seizures, or peripheral neuropathy occur in approximately one per million recipients. However, since 1989 a new pattern of allergic reactions has been described (itching, urticaria, and rarely angioedema of the face), which is more likely in those with a previous history of allergy and occasionally may require hospitalization and corticosteroid therapy (76). The inactivated mouse brain-derived vaccine is now commonly replaced by cell culture-based vaccines (107) (see Table 1).
Since the late 1980s, a live attenuated Japanese encephalitis vaccine (produced by passing the virus through weanling mice, then culturing in primary baby hamster kidney cells), has been given to over 100 million children in China. It is safe and immunogenic. In a case control study, two doses one year apart were shown to be 97.5% effective (35); in another study, a single dose of vaccine was shown to be an efficacious prevention technique when administered only days or weeks before exposure to infection (06). The vaccine was licensed in China in 1988 and is being used in other Asian countries, but it is not yet available in the West. In addition, a chimeric vaccine is being developed in which the structural proteins of the long-established 17D yellow fever vaccine are replaced with the same proteins from the live attenuated Japanese encephalitis vaccine (04). It has been shown to be safe and immunogenic (71). In a Cochrane review, authors have concluded that because only one of three vaccines have been directly investigated for effectiveness in a randomized controlled trial, it is not possible to compare the effectiveness of currently used vaccines in the prevention of clinical disease (82).
Table 1. Vaccines for Japanese Encephalitis
|
|
Live attenuated vaccine (SA 14-14-2 strain): | |
|
• First dose is given subcutaneously at 8 months of age, followed by a booster dose at 2 years of age. | ||
|
|
Inactivated, Vero cell-derived, alum-adjuvanted vaccine (SA 14-14-2 strain): | |
|
• Primary immunization consists of two intramuscular doses, 4 weeks apart. A booster is recommended after year 1. | ||
|
|
Inactivated, Vero cell-derived vaccines (Beijing-1 strain): | |
|
• Primary immunization consists of three doses at days 0, 7, and 28, or two doses given preferably 4 weeks apart (0.25 ml for children < 3 years, 0.5 ml for all other ages). One booster is recommended 12 to 14 months after completion of the primary immunization, and thereafter every 3 years. | ||
|
|
Live chimeric vaccine (with yellow fever 17D as backbone): | |
|
• A single dose is recommended. | ||
|
| ||
In a multicentric randomized-controlled study, Yan Li and colleagues demonstrated that simultaneous administration of live-attenuated Japanese encephalitis vaccine and measles and rubella vaccine does not adversely affect measles and rubella seropositivity. Therefore, both vaccines can be administered together in countries where Japanese encephalitis is endemic (57).
Japanese encephalitis vaccine is recommended for international travelers who intend to spend a month or longer in endemic areas during the Japanese encephalitis virus transmission season and for laboratory workers with a potential for exposure to infectious Japanese encephalitis virus (26). However, considering the variability of Japanese encephalitis from year to year, its unpredictability, and the poor reliability of some epidemiological data, identifying areas of epidemic transmission is difficult, and wider use of the vaccine has been advocated (43; 12). A newer purified, inactivated Japanese encephalitis virus vaccine (IC51) has been developed, which is manufactured in a Vero cell culture substrate. Studies show that the vaccine is both safe and immunogenic. This vaccine is currently aimed for international travelers (45).
Adverse events following receipt of inactivated mouse-brain-derived Japanese encephalitis vaccine reported to the United States Vaccine Adverse Event Reporting System from 1999 to 2009 were reviewed (60). During this period, 300 adverse event reports following vaccination were received (24 per 100,000 doses distributed). Out of this, 106 (35%) were classified as hypersensitivity reactions (8.4 per 100,000 doses), and four (1%) were classified as neurologic events (0.3 per 100,000 doses). Only 23 reports (8%) described serious adverse events (1.8 per 100,000 doses distributed).
A study from China observed that high incidence of childhood onset myasthenia gravis in Chinese population is linked to universal live-attenuated Japanese encephalitis vaccination. The authors of this study suggested that live-attenuated Japanese encephalitis vaccine induced an autoimmunity against the acetylcholine receptor through mechanism of molecular mimicry (34).
A One Health approach that integrates human, animal, mosquito, and environmental surveillance is crucial to understanding the epidemiology of Japanese encephalitis virus. Although human case surveillance provides limited early signals of transmission, mosquito and animal surveillance can provide early warning signals that enable the implementation of public health measures. Travelers to endemic areas should be made aware of the risk and advised on vaccination and mosquito bite avoidance measures. The evolving epidemiology of Japanese encephalitis virus in Australia has implications for the possible threat the disease may pose to other regions (65).
Differential diagnosis
Confusing conditions
Infection with Japanese encephalitis virus may be asymptomatic or may cause febrile illness, meningitis, myelitis, or encephalitis. Encephalitis is the most commonly recognized presentation and is clinically indistinguishable from other causes of an acute encephalitis syndrome. Clinically, a case of acute encephalitis syndrome is defined as a person of any age, at any time of year, with the acute onset of fever and a change in mental status (including symptoms such as confusion, disorientation, coma, or inability to talk) and new onset of seizures (excluding simple febrile seizures). Other early clinical findings may include an increase in irritability, somnolence, or abnormal behavior greater than that seen with usual febrile illness (106). Lymphocytic CSF with an elevated protein and a normal glucose ratio supports the diagnosis, but other causes must be excluded, and virological confirmation is needed. The differential diagnosis is broad, particularly in adults, and can be divided into viral encephalitides, nonviral CNS infections, infectious diseases with CNS manifestations, and noninfectious diseases:
|
Viral encephalitides | |
|
• Arboviruses | |
|
Nonviral CNS infections | |
|
• Acute bacterial meningitis | |
|
Infectious diseases with CNS manifestations | |
|
• Febrile convulsions | |
|
Noninfectious diseases | |
|
• Reye syndrome | |
Japanese encephalitis may be confused with other arboviral encephalitides, particularly in areas where more than one virus is endemic. The flaviviruses, Murray valley, West Nile, and even Dengue can cause similar illnesses (42; 90). Outbreaks of Nipah virus encephalitis (21), human enterovirus 71 (105), and Chandipura virus (78) have shown the need to be cautious before attributing outbreaks of encephalitis to Japanese encephalitis. Distinguishing Japanese encephalitis from partially pre-treated bacterial meningitis and cerebral malaria may be particularly difficult, because in many parts of the tropics antibiotic and antimalarial drugs are readily available without prescription. On the basis of their observations in an endemic region, Dubot-Pérès and colleagues cautioned that detection of anti-Japanese encephalitis virus IgM in patients with acute encephalitic syndrome may be deceptive, and it is advisable to consider other treatable diseases, particularly bacterial infections before labelling the diagnosis of Japanese encephalitis (25). In 6% of CSF anti-Japanese encephalitis virus IgM positive cases, evidence of a pathogen other than Japanese encephalitis was confirmed.
Garg and co-workers described an unusual case of acute encephalitis syndrome positive for immunoglobulin-M antibodies (in serum as well as in cerebrospinal fluid) against both dengue virus and Japanese encephalitis virus. Co-positivity in an endemic region (both for dengue and Japanese encephalitis) is possible either because of co-invasion or because of co-detection resulting from well-described cross reactivity of serological tests between dengue virus and Japanese encephalitis virus (27). In one case, the patient had MRI evidence of bilateral thalamic and brainstem involvement, and serology was positive for both dengue and Japanese encephalitis (85).
Acute flaccid paralysis due to Japanese encephalitis virus must be distinguished from other viruses that attack anterior horn cells (poliovirus, nonpolio-enteroviruses, and West Nile virus) and from post-infectious causes of weakness such as Guillain-Barré syndrome. Poliomyelitis and Japanese encephalitis virus myelitis may be clinically indistinguishable, although the presence of bladder involvement suggests the latter (92). Of the enteroviruses that cause flaccid paralysis, enterovirus 71 is the most important. It is especially likely if paralysis occurs during an outbreak of hand foot and mouth disease (67; 40). Differentiating Japanese encephalitis virus myelitis from the acute inflammatory demyelinating polyneuropathy form of Guillain-Barré syndrome is not normally difficult, because the latter typically occurs sometime after an acute febrile illness and has symmetrical sensory and motor nerve involvement. Distinguishing the acute motor axonal neuropathy form of Guillain-Barré syndrome is more difficult because it too affects only lower motor nerves, and large epidemics have been described in Asia (66). However, it is usually symmetrical and post-infectious rather than occurring during an acute febrile illness.
Japanese encephalitis infection, like herpes simplex encephalitis, can trigger anti-N-methyl-d-aspartate receptor (NMDAR) immunoglobulin G (IgG) synthesis and autoimmune encephalitis (20; 97). A study by Ma and colleagues revealed that among 63 patients with Japanese encephalitis, five patients relapsed during the convalescence phase (63). Four younger patients presented with choreoathetosis, and one patient presented with the psychiatric and behavioral symptoms. NMDAR antibodies in the CSF of three patients were positive, and they were diagnosed with anti-NMDAR encephalitis. In all other patients, anti-N-methyl-d-aspartate receptor antibodies testing was negative. Liu and colleagues reported a series of 31 children with Japanese virus encephalitis who were prospectively studied for development of antineuronal autoantibodies during the course of their encephalitis (61). Of 31 children, five developed an apparent relapse of their encephalitis: of these five children, two had developed anti-NMDAR antibodies, one anti-γ-aminobutyric acid-B receptor (GABABR) antibodies, and two antibodies to unknown neural membrane antigens. The exact pathogenesis of the virus encephalitis induced N-methyl-D-aspartate receptor or other membrane encephalitis is not exactly known. It has been hypothesized that synaptic autoimmunity develops following release of antigens because of virus induced neuronal damage. Coinfection of neurocysticercosis and Japanese encephalitis has frequently been noted in the endemic regions, often resulting in poor outcome (32; 96).
Diagnostic workup
In most patients with Japanese encephalitis, there is a peripheral neutrophil leukocytosis. Typically, there is a moderate CSF pleocytosis of 10 to 100 cells per mm3, with predominant lymphocytes, mildly elevated protein (50 to 200 mg%) and a normal glucose ratio. However, polymorphonuclear cells may predominate early in the disease, or there may be no CSF pleocytosis.
Computed tomography may show bilateral nonenhancing low-density areas in the thalamus, basal ganglia, midbrain, pons, and medulla (69). The most consistent MRI findings in Japanese encephalitis are bilateral thalamic lesions with or without hemorrhagic changes. Lesions are also noted in the substantia nigra, brainstem, cerebellum, cerebral cortex, and white matter. Lesions in the substantia nigra may be characteristic of patients with parkinsonian features (77). On MRI, there may be more extensive changes and characteristic thalamic lesions of mixed intensity on T1 and T2; weighted scans are suggestive of hemorrhage (55). These changes may be useful in distinguishing Japanese encephalitis from Herpes simplex encephalitis, where the changes are characteristically frontotemporal. Medial temporal MR lesions have been reported in several other diseases of central nervous system-like paraneoplastic limbic encephalitis and neurosyphilis.
In Japanese encephalitis, medial temporal lesions are often associated with bilateral thalamic or midbrain involvement. Temporal lobe involvement in Japanese encephalitis dominantly affects the hippocampus (31; 47).
A variety of electroencephalographic abnormalities have been reported in Japanese encephalitis including theta and delta coma, burst suppression, epileptiform activity, and occasionally alpha coma, but none seem to be diagnostic.
Specific tests for diagnosing Japanese encephalitis demonstrate either the presence of the virus or the antibody to the virus. Attempts to isolate Japanese encephalitis virus from clinical specimens are usually unsuccessful because of low titers and the rapid production of neutralizing antibody. Isolates are sometimes obtained from CSF (in which case it is associated with a failure of antibody production and a high mortality rate) (56) or from brain tissue (either at autopsy or post-mortem needle biopsy). Japanese encephalitis virus RNA has been detected in human CSF samples using reverse transcriptase polymerase chain reaction (42). However, its reliability as a routine diagnostic test has yet to be shown. Of the various serological methods available, the IgM capture ELISA has proved the most useful. The presence of anti-Japanese encephalitis virus IgM in the CSF has a sensitivity and specificity of less than 95% for CNS infection with Japanese encephalitis virus (10). The ELISA was modified to a simple “dot-blot” nitrocellulose membrane-based format for diagnosis of Japanese encephalitis for use in the rural settings where the disease often occurs (93).
World Health Organization recommended laboratory criteria for confirmation (106):
|
(1) Presence of Japanese encephalitis virus-specific IgM antibody in a single sample of cerebrospinal fluid or serum, an IgM-capture ELISA specifically for Japanese encephalitis virus. | |
|
(2) Detection of Japanese encephalitis virus antigens in tissue by immunohistochemistry. | |
|
(3) Detection of Japanese encephalitis virus genome in serum, plasma, blood, cerebrospinal fluid, or tissue by reverse transcriptase polymerase chain reaction or an equally sensitive and specific nucleic acid amplification test. | |
|
(4) Isolation of Japanese encephalitis virus in serum, plasma, blood, cerebrospinal fluid, or tissue. | |
|
(5) Detection of a 4-fold or greater rise in Japanese encephalitis virus-specific antibody as measured by hemagglutination inhibition or plaque reduction neutralization assay in serum collected during the acute and convalescent phase of illness. |
Management
There is currently no specific antiviral treatment for Japanese encephalitis, though a number of compounds have shown some efficacy against the virus in vitro or in animal models including nitric oxide, ribavirin and interferon alpha (81; 94). In a randomized, controlled trial, oral ribavirin has not been found effective in patients with Japanese encephalitis (54).
Interferon alpha-2a was tested in a double-blind placebo-controlled trial on children with Japanese encephalitis, but with negative results (81; 94; 30). Minocycline, in an experimental study, has been found to confer complete protection in mice following Japanese encephalitis infection. Following treatment with minocycline neuronal apoptosis, microglial activation, active caspase activity, proinflammatory mediators, and viral titer were markedly decreased in Japanese encephalitis-infected mice on the ninth day (68). However, a randomized trial failed to provide desired benefit in pediatric patients with acute encephalitis syndrome (51). The study included patients of Japanese encephalitis as well.
A randomized double-blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis was conducted in Nepal to assess the feasibility. It was observed that intravenous immunoglobulin augments the development of neutralizing antibodies in these patients. The authors conclude that intravenous immunoglobulin is an option for Japanese encephalitis treatment; however, therapeutic potential of intravenous immunoglobulin needs to be investigated (79). Chen and colleagues assessed intravenous immunoglobulin in 124 children with severe Japanese encephalitis and noted that the patients who received intravenous immunoglobulin had a shorter duration of unconsciousness and number of days of seizures, a dull response to light, the pyramidal sign, and the meningeal-irritation sign (14). In Korea, Son and colleagues treated eight patients with combination therapy that included immunoglobulin, ribavirin, and interferon alpha-2b (95). During follow-up, four treated patients (50%) showed partial recovery, whereas one patient (12.5%) showed complete recovery. Among the three patients who received supportive management only, one (33.3%) showed partial recovery, and the clinical course of the other two remained unchanged.
Patients are given supportive treatment that involves controlling convulsions with raised intracranial pressure when they occur. Corticosteroids were given for many years, but a double-blind randomized placebo-controlled trial of dexamethasone failed to show any benefit (39). Aspiration pneumonia is a common occurrence in patients with a reduced gag reflex. Careful nursing care and physiotherapy are needed to reduce the risk of bedsores, malnutrition, and contractures.
Special considerations
Pregnancy
Japanese encephalitis occurred in five pregnant women during an epidemic in India, two of whom aborted and one of who had an apparently normal child. The virus was isolated from one of the aborted fetuses (13).
Media
References
- 01
- Aihara H, Takasaki T, Matsutani T, Suzuki R, Kurane I. Establishment and characterization of Japanese encephalitis virus-specific, human CD4+ T-cell clones: Flavivirus cross-reactivity, protein recognition, and cytotoxic activity. J Virol 1998;72:8032-6. PMID 9733842
- 02
- Akiba T, Osaka K, Tang S, et al. Analysis of Japanese encephalitis epidemic in Western Nepal in 1997. Epidemiol Infect 2001;126:81-8. PMID 11293685
- 03
- Arai S, Matsunaga Y, Takasaki T, et al. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. Jpn J Infect Dis 2008;61(5):333-8. PMID 18806337
- 04
- Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol 2001;75:934-42. PMID 11134306
- 05
- Baldwin Z, Hueston L, Roberts-Witteveen A, et al. The seroprevalence of antibodies to Japanese encephalitis virus in five New South Wales towns at high risk of infection, 2022: a cross-sectional serosurvey. Med J Aust 2024;220(11):561-5. PMID 38815982
- 06
- Bista MB, Banerjee MK, Shin SH, et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001;358(9284):791-5. PMID 11564484
- 07
- Biyani S, Garg RK, Jain A, et al. Toll-like receptor-3 gene polymorphism in patients with Japanese encephalitis. J Neuroimmunol 2015;286:71-6. PMID 26298326
- 08
- Borah J, Dutta P, Khan SA, Mahanta J. A comparison of clinical features of Japanese encephalitis virus infection in the adult and pediatric age group with acute encephalitis syndrome. J Clin Virol 2011;52(1):45-9. PMID 21715224
- 09
- Briese T, Jia XY, Huang C, Grady LJ, Lipkin WI. Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis. Lancet 1999;354:1261-2. PMID 10520637
- 10
- Burke DS, Nisalak A, Ussery MA, Laorakpongse T, Chantavibul S. Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis 1985;151:1093-99. PMID 2987367
- 11
- Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011;89(10):766-74. PMID 22084515
- 12
- Centers for Disease Control and Prevention. Japanese Encephalitis Among Three U.S. Travelers Returning from Asia, 2003-2008. MMWR Morb Mortal Wkly Rep 2009;58(27):737-40. PMID 19609246
- 13
- Chaturvedi UC, Mathur A, Chandra A, Das SK, Tandon HO, Singh UK. Transplacental infection with Japanese encephalitis virus. J Infect Dis 1980;141:712-5. PMID 6248601
- 14
- Chen D, Peng X, Zhan Y, Wu P, Jiang L, Hu Y. Efficacy and safety of intravenous high-dose immunoglobulin in treatment of the severe form of Japanese encephalitis. Neurol Sci 2022a;43(6):3911-8. PMID 35044559
- 15
- Chen DD, Peng XL, Cheng H, et al. Risk factors and a predictive model for the development of epilepsy after Japanese encephalitis. Seizure 2022b;99:105-12. PMID 35636157
- 16
- Chen HY, Yang CY, Hsieh CY, et al. Long-term neurological and healthcare burden of adults with Japanese encephalitis: a nationwide study 2000-2015. PLoS Negl Trop Dis 2021;15(9):e0009703. PMID 34520457
- 17
- Chen WR, Rico-Hesse R, Tesh RB. A new genotype of Japanese encephalitis virus from Indonesia. Am J Trop Med Hyg 1992;47(1):61-9. PMID 1322071
- 18
- Chen WR, Tesh RB, Rico-Hesse R. Genetic variation of Japanese encephalitis virus in nature. J Gen Virol 1990;71(Pt 12):2915-22. PMID 2273391
- 19
- Chen Y, Maguire T, Hileman RE, et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulphate. Nat Med 1997;3:866-71. PMID 9256277
- 20
- Chen Z, Wang X, Ashraf U, et al. Activation of neuronal N-methyl-D-aspartate receptor plays a pivotal role in Japanese encephalitis virus-induced neuronal cell damage. J Neuroinflammation 2018;15(1):238. PMID 30144801
- 21
- Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 1999;354:1257-9. PMID 10520635
- 22
- Chung CC, Lee SS, Chen YS, et al. Acute flaccid paralysis as an unusual presenting symptom of Japanese encephalitis: a case report and review of the literature. Infection 2007;35(1):30-2. PMID 17297587
- 23
- Diagana M, Preux PM, Dumas M. Japanese encephalitis revisited. J Neurol Sci 2007;262(1-2):165-70. PMID 17643451
- 24
- Dickerson RB, Newton JR, Hansen JE. Diagnosis and immediate prognosis of Japanese B encephalitis. Am J Med 1952;12:277-88. PMID 14902875
- 25
- Dubot-Peres A, Sengvilaipaseuth O, Chanthongthip A, Newton PN, de Lamballerie X. How many patients with anti-JEV IgM in cerebrospinal fluid really have Japanese encephalitis? Lancet Infect Dis 2015;15(12):1376-7. PMID 26607119
- 26
- Fischer M, Lindsey N, Staples JE, et al. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(RR-1):1-27. PMID 20224546
- 27
- Garg RK, Malhotra HS, Gupta A, et al. Concurrent dengue virus and Japanese encephalitis virus infection of the brain: is it co-infection or co-detection. Infection 2012;40(5):589-93. PMID 22696307
- 28
- German AC, Myint KS, Mai NT, et al. A preliminary neuropathological study of Japanese encephalitis in humans and a mouse model. Trans R Soc Trop Med Hyg 2006;100(12):1135-45. PMID 16814333
- 29
- Ghoshal A, Das S, Ghosh S, et al. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 2007;55(5):483-96. PMID 17203475
- 30
- Gould EA, Solomon T, Mackenzie JS. Does antiviral therapy have a role in the control of Japanese encephalitis. Antiviral Res 2008;78(1):140-9. PMID 18053589
- 31
- Handique SK, Das RR, Barman K, et al. Temporal lobe involvement in Japanese encephalitis: problems in differential diagnosis. AJNR Am J Neuroradiol 2006;27(5):1027-31. PMID 16687537
- 32
- Handique SK, Das RR, Saharia B, Das P, Buragohain R, Saikia P. Coinfection of Japanese encephalitis with neurocysticercosis: an imaging study. AJNR Am J Neuroradiol 2008;29(1):170-5. PMID 17928378
- 33
- Hanna JN, Ritchie SA, Phillips DA, et al. Japanese encephalitis in north Queensland, Australia. Med J Aust 1999;7:533-6. PMID 10397044
- 34
- He D, Zhang H, Xiao J, et al. Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis. Ann Neurol 2018;84(3):386-400. PMID 30246904
- 35
- Hennessy S, Zhengle L, Tsai TF, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case control study. Lancet 1996;347:1583-6. PMID 8667866
- 36
- Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg 2010;82(5):930-6. PMID 20439978
- 37
- Hills SL, Netravathi M, Solomon T. Japanese encephalitis among adults: A review. Am J Trop Med Hyg 2023;108(5):860-4. PMID 37037440
- 38
- Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988;319:608-14. PMID 2842677
- 39
- Hoke CH, Vaughn DW, Nisalak A, et al. Effect of high dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J Infect Dis 1992;165:631-7. PMID 1313068
- 40
- Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. Neurologic complications in children with enterovirus 71 infection. N Engl J Med 1999;341:936-42. PMID 10498488
- 41
- Huy BV, Tu HC, Luan TV, Lindqvist R. Early mental and neurological sequelae after Japanese B encephalitis. Southeast Asian J Trop Med Public Health 1994;25:549-53. PMID 7777924
- 42
- Igarashi A, Tanaka M, Morita K, et al. Detection of West Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. Microbiol Immunol 1994;38:827-30. PMID 7869964
- 43
- Innis BL. Japanese encephalitis. In: Exotic Viral Infections. Porterfield JS, editor. London: Chapman and Hall, 1995:147-74.
- 44
- Jain P, Singh AK, Khan DN, et al. Trend of Japanese encephalitis in Uttar Pradesh, India from 2011 to 2013. Epidemiol Infect 2016;144(2):363-70. PMID 26112391
- 45
- Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev Vaccines 2008;7(5):689-93. PMID 18564023
- 46
- Johnson RT, Burke DS, Elwell M, et al. Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann Neur 1985;18:567-73. PMID 3000282
- 47
- Jung KY, Chung CS, Park KW. Bilateral medial temporal lesions in Japanese encephalitis. Neurology 2007;68(16):1319. PMID 17438225
- 48
- Kumar P, Sulochana P, Nirmala G, Chandrashekar R, Haridattatreya M, Satchidanandam V. Impaired T helper 1 function of nonstructural protein 3-specific T cells in Japanese patients with encephalitis with neurological sequelae. J Infect Dis 2004a;189(5):880-91. PMID 14976606
- 49
- Kumar P, Sulochana P, Nirmala G, Haridattatreya M, Satchidanandam V. Conserved amino acids 193-324 of non-structural protein 3 are a dominant source of peptide determinants for CD4+ and CD8+ T cells in a healthy Japanese encephalitis virus-endemic cohort. J Gen Virol 2004b;85(Pt 5):1131-43. PMID 15105530
- 50
- Kumar P, Uchil PD, Sulochana P, et al. Screening for T cell-eliciting proteins of Japanese encephalitis virus in a healthy JE-endemic human cohort using recombinant baculovirus-infected insect cell preparations. Arch Virol 2003;148(8):1569-91. PMID 12898332
- 51
- Kumar R, Basu A, Sinha S, et al. Role of oral Minocycline in acute encephalitis syndrome in India—a randomized controlled trial. BMC Infect Dis 2016;16:67. PMID 26847071
- 52
- Kumar R, Mathur A, Kumar A, Sharma S, Chakraborty S, Chaturvedi U. Clinical features and prognostic indicators of Japanese encephalitis in children in Lucknow (India). Indian J Med Res 1990;91:321-7. PMID 2176644
- 53
- Kumar R, Mathur A, Singh KB, et al. Clinical sequelae of Japanese encephalitis in children. Indian J Med Res 1993;97:9-13. PMID 8387460
- 54
- Kumar R, Tripathi P, Baranwal M, et al. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin Infect Dis 2009;48(4):400-6. PMID 19143532
- 55
- Kumar S, Misra UK, Kalita J, Sawani V, Gupta RK, Gujral R. MRI in Japanese encephalitis. Neuroradiology 1997;39:180-4. PMID 9106289
- 56
- Leake CJ, Burke DS, Nisalak A, Hoke CH. Isolation of Japanese encephalitis virus from clinical specimens using a continuous mosquito cell line. Am J Trop Med Hyg 1986;35:1045-50. PMID 3021009
- 57
- Li Y, Chu SY, Yue C, et al. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial. Lancet Infect Dis 2019;19(4):402-9. PMID 30833160
- 58
- Libraty DH, Nisalak A, Endy TP, Suntayakorn S, Vaughn DW, Innis BL. Clinical and immunological risk factors for severe disease in Japanese encephalitis. Trans R Soc Trop Med Hyg 2002;96(2):173-8. PMID 12055808
- 59
- Lincoln AF, Silvertson SE. Acute phase of Japanese B encephalitis. Two hundred and one cases in American soldiers, Korea 1950. JAMA 1952;150:268-73.
- 60
- Lindsey NP, Staples JE, Jones JF, et al. Adverse event reports following Japanese encephalitis vaccination in the United States, 1999-2009. Vaccine 2010;29(1):58-64. PMID 20970488
- 61
- Liu B, Liu J, Sun H, et al. Autoimmune encephalitis after Japanese encephalitis in children: a prospective study. J Neurol Sci 2021;424:117394. PMID 33773410
- 62
- Liu TH, Liang LC, Wang CC, Liu HC, Chen WJ. The blood-brain barrier in the cerebrum is the initial site for the Japanese encephalitis virus entering the central nervous system. J Neurovirol 2008;14(6):514-21. PMID 19023687
- 63
- Ma J, Han W, Jiang L. Japanese encephalitis-induced anti-N-methyl-d-aspartate receptor encephalitis: a hospital-based prospective study. Brain Dev 2020;42(2):179-84. PMID 31563418
- 64
- Ma'roef CN, Dhenni R, Megawati D, et al. Japanese encephalitis virus infection in non-encephalitic acute febrile illness patients. PLoS Negl Trop Dis 2020;14(7):e0008454. PMID 32663209
- 65
- McGuinness SL, Lau CL, Leder K. The evolving Japanese encephalitis situation in Australia and implications for travel medicine. J Travel Med 2023;30(2):taad029. PMID 36869722
- 66
- McKhann GM, Cornblath DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 1991;338:593-7. PMID 1679153
- 67
- Melnick JL. Enterovirus type 71 infections: a varied clinical pattern sometimes mimicking paralytic poliomyelitis. Rev Infect Dis 1984;6:S387-90. PMID 6330839
- 68
- Mishra MK, Basu A. Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. J Neurochem 2008;105(5):1582-95. PMID 18208541
- 69
- Misra UK, Kalita J, Jain KK, Mathur A. Radiological and neurophysiological changes in Japanese encephalitis. J Neurol Neurosurg Psychiatry 1994;57:1484-7. PMID 7798977
- 70
- Miyake M. The pathology of Japanese encephalitis. Bulletin of the World Health Organization 1964;30:153-60. PMID 14153404
- 71
- Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003;188(8):1213-30. PMID 14551893
- 72
- Monath TP, Heinz FX. Flaviviruses. In: Fields BN, Knipe DM, Howley M, editors. Fields virology. Philadelphia: Lippincott-Raven, 1996:961-1034.
- 73
- Myint KS, Kipar A, Jarman RG, et al. Neuropathogenesis of Japanese encephalitis in a primate model. PLoS Negl Trop Dis 2014;8(8):e2980. PMID 25102067
- 74
- Ooi MH, Lewthwaite P, Lai BF, et al. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in central Sarawak, Malaysia, 1997-2005. Clin Infect Dis 2008;47(4):458-68. PMID 18616397
- 75
- Petersen LR, Roehrig JT, Hughes JM. West Nile virus encephalitis. N Engl J Med 2002;347(16):1225-6. PMID 12270973
- 76
- Plesner A, Ronne T, Wachmann H. Case-control study of allergic reactions to Japanese encephalitis vaccine. Vaccine 2000;18:1830-6. PMID 10699331
- 77
- Pradhan S, Pandey N, Shashank S, Gupta RK, Mathur A. Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis. Neurology 1999;10:1781-6. PMID 10563628
- 78
- Rao BL, Basu A, Wairagkar NS, et al. A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus. Lancet 2004;364(9437):869-74. PMID 15351194
- 79
- Rayamajhi A, Nightingale S, Bhatta NK, et al. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One 2015;10(4):e0122608. PMID 25886645
- 80
- Sarkari NB, Thacker AK, Barthwal SP, et al. Japanese encephalitis (JE). Part I: clinical profile of 1,282 adult acute cases of four epidemics. J Neurol 2012;259(1):47-57. PMID 21678123
- 81
- Saxena SK, Singh A, Mathur A. Antiviral effect of nitric oxide during Japanese encephalitis virus infection. Int J Exp Pathol 2000;81:165-72. PMID 10762444
- 82
- Schioler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev 2007;(3):CD004263. PMID 17636750
- 83
- Schneider RJ, Firestone MH, Edelman R, Chiewanich P, Pornpibul R. Clinical sequelae after Japanese encephalitis: a one year follow up study in Thailand. Southeast Asian J Trop Med Public Health 1974;5:560-8. PMID 4376275
- 84
- Singh AK, Kharya P, Agarwal V, et al. Japanese encephalitis in Uttar Pradesh, India: a situational analysis. J Family Med Prim Care 2020;9(7):3716-21. PMID 33102356
- 85
- Sivamani K, Dhir V, Singh S, Sharma A. Diagnostic dilemma–dengue or Japanese encephalitis? Neurol India 2017;65(1):105-7. PMID 28084251
- 86
- Solomon T. Current concepts: Flavivirus encephalitis. New Engl J Med 2004;351:370-8. PMID 15269317
- 87
- Solomon T, Cardosa MJ. Emerging arboviral encephalitis. BMJ 2000;321:1484-5. PMID 11118162
- 88
- Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. J Neurol Neurosurg Psychiatry 2000a;68:405-15. PMID 10727474
- 89
- Solomon T, Dung NM, Kneen R, et al. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain 2002;125(Pt 5):1084-93. PMID 11960897
- 90
- Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet 2000b;355:1053-9. PMID 10744091
- 91
- Solomon T, Kneen R. Interactive clinical case report: CNS infections in Vietnam: “off legs cause”. Transactions of the Royal Society of Tropical Medicine and Hygiene 2000;94:356.
- 92
- Solomon T, Kneen R, Dung NM, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet 1998a;351:1094-7. PMID 9660579
- 93
- Solomon T, Thao L, Dung NM, et al. Rapid diagnosis of Japanese encephalitis by using an IgM dot enzyme immunoassay. Journal of Clin Microbiol 1998b;36:2030-4. PMID 9650956
- 94
- Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. In: McKenzie JS, Barrett AD, Deubel V, editors. Current topics in microbiology and immunology: Japanese encephalitis and West Nile Virus infections. Springer-Verlag, 2002:171-94.
- 95
- Son H, Sunwoo JS, Lee SK, Chu K, Lee ST. Clinical outcomes of Japanese encephalitis after combination treatment of immunoglobulin, ribavirin, and interferon-α2b. J Clin Neurol 2021;17(3):428-34. PMID 34184451
- 96
- Takia L, Angurana SK, Suthar R, Nallasamy K, Ahuja CK. Co-infection of neurocysticercosis with Japanese encephalitis: coincidence or synchronism? Trop Doct 2020;50(3):261-3. PMID 32476601
- 97
- Tian M, Li J, Lei W, Shu X. Japanese encephalitis virus-induced anti-N-methyl-D-aspartate receptor encephalitis: a case report and review of literature. Neuropediatrics 2019;50(2):111-5. PMID 30620950
- 98
- Tiroumourougane SV, Raghava P, Srinivasan S. Japanese viral encephalitis. Postgrad Med J 2002;78:205-15. PMID 11930023
- 99
- Uchil PD, Satchidanandam V. Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent. Am J Trop Med Hyg 2001;65(3):242-51. PMID 11561712
- 100
- Vaughn DW, Hoke CH. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 1992;14:197-221. PMID 1337744
- 101
- Waller C, Tiemensma M, Currie BJ, Williams DT, Baird RW, Krause VL. Japanese encephalitis in Australia - a sentinel case. N Engl J Med 2022;387(7):661-2. PMID 36070717
- 102
- Wang G, Li H, Yang X, et al. Guillain-Barré syndrome associated with JEV infection. N Engl J Med 2020;383(12):1188-90. PMID 32937054
- 103
- Wang G, Zhong L, Wang M, et al. Peripheral nerve injury associated with JEV infection in high endemic regions, 2016-2020: a multicenter retrospective study in China. Emerg Microbes Infect 2024;13(1):2337677. PMID 38578315
- 104
- Winter PM, Dung NM, Loan HT, et al. Proinflammatory cytokines and chemokines in humans with Japanese encephalitis. J Infect Dis 2004;190(9):1618-26. PMID 15478067
- 105
- Wong KT, Lum LC, Lam SK. Enterovirus 71 infection and neurologic complications. N Engl J Med 2000 Feb 3;342(5):356-8. PMID 10660401
- 106
- World Health Organization. Japanese encephalitis surveillance standards. WHO-recommended standards for surveillance of selected vaccine-preventable diseases WHO/V&B/03.01. Accessed: December 1, 2012. http://www.path.org/files/WHO_surveillance_standards_JE.pdf. January 2006.
- 107
- World Health Organization. International travel and health; Japanese encephalitis; Vaccines. Japanese encephalitis. Accessed November 3, 2013.
- 108
- World Health Organization. Japanese encephalitis. Fact sheet No 386, March 2014. Japanese encephalitis fact sheet. Accessed September 9, 2014.
- 109
- Wu D, Chen X, Liu W, et al. Emergence of Japanese encephalitis among adults 40 years of age or older in northern China: epidemiological and clinical characteristics. Transbound Emerg Dis 2021;68(6):3415-23. PMID 33283432
- 110
- Yakob L, Hu W, Frentiu FD, et al. Japanese encephalitis emergence in Australia: The potential population at risk. Clin Infect Dis 2023;76(2):335-7. PMID 36184991
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Ravindra Kumar Garg DM FRCP
Dr. Garg of King George's Medical University in Lucknow, India, has no relevant financial relationships to disclose.
See Profile
Editor
-
John E Greenlee MD
Dr. Greenlee of the University of Utah School of Medicine has no relevant financial relationships to disclose.
See Profile
Former Authors
- Tom Solomon MD
Patient Profile
- Age range of presentation
-
- 1 month to 65+ years
- Sex preponderance
-
- male=female
- Heredity
-
- none
- Population groups selectively affected
-
- inhabitants of rural Southeast Asia
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-10
-
- Japanese encephalitis: A83.0
- ICD-11
-
- Japanese encephalitis: 1C85
- Japanese encephalitis virus: XN9ZK
- Encephalitis, Japanese, live attenuated: XM47S0
- Encephalitis, Japanese, inactivated, whole virus: XM0LB5
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Infectious Disorders
Rabies
Dec. 10, 2024
-
Infectious Disorders
Malaria
Dec. 10, 2024
-
Peripheral Neuropathies
Neuropathies associated with cytomegalovirus infection
Nov. 16, 2024
-
Infectious Disorders
Genital herpes: neurologic complications
Nov. 15, 2024
-
Infectious Disorders
Neurocysticercosis
Nov. 12, 2024
-
Infectious Disorders
Trichinosis
Nov. 12, 2024
-
Infectious Disorders
Zika virus: neurologic complications
Oct. 08, 2024
